■ Schizophrenia

Alkomiet Hasan, Peter Falkai, Isabell Lehmann, Wolfgang Gaebel

Dtsch Arztebl Int. 2020 Jun; 117(24): 412–429

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477695/

 

■ EPA guidance on assessment of negative symptoms in schizophrenia

  1. Galderisi, A. Mucci, S. Dollfus, M. Nordentoft, et al

Eur Psychiatry. 2021; 64(1): e23

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080207/

 

■ EPA guidance on treatment of negative symptoms in schizophrenia

  1. Galderisi, S. Kaiser, I. Bitter, et al

Eur Psychiatry. 2021; 64(1): e21

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057437/

 

■ Pharmacological treatment of schizophrenia: Japanese expert consensus

Hitoshi Sakurai, Norio Yasui-Furukori, Takefumi Suzuki, et al

Pharmacopsychiatry. 2021 Mar; 54(2): 60–67

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946533/

 

■ Guidance on the clinical understanding and use of long-acting injectable antipsychotics in schizophrenia: Hong Kong Consensus Statements

Michael Ming Cheuk Wong, Albert Kar Kin Chung, Timothy Ming Hong Yeung, et al

CNS Neurosci Ther. 2021 Mar; 27(Suppl 1): 5–11

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869935/

 

■ Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study

Silvana Galderisi, Marc De Hert, Stefano Del Prato, et al

Eur Psychiatry. 2021; 64(1): e7

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057390/

 

■  Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Blog Internet Médica – www.internetmedica.com.br

Data: junho 2021